Targeted therapy in HCC
| Drug | Control | Line | Status | Reference |
|---|---|---|---|---|
| Sorafenib | Placebo | First line | Approved (US FDA, NMPA) | Llovet et al., 200897; Cheng et al., 200998 |
| Lenvatinib | Sorafenib | First line | Approved (US FDA, NMPA) | Kudo et al., 2018115 |
| Sunitinib | Sorafenib | First line | Failed | Cheng et al., 2013112 |
| Linifanib | Sorafenib | First line | Failed | Cainap et al., 2015113 |
| Dovotinib | Sorafenib | First line | Failed | Cheng et al., 2016144 |
| Donafenib | Sorafenib | First line | Approved (NMPA) | Bi et al., 2020119 |
| Apatinib | Sorafenib | Second line | Approved (NMPA) | He et al., 2020134 |
| Regorafenib | Non-candidate groups | Second line | Approved (US FDA, NMPA) | Kuzuya et al., 2019123; Teufel et al., 2019122 |
| Cabozantinib | Non-candidate groups | Second line | Approved (US FDA) | Kuzuya et al., 2019123; Abou-Alfa et al., 2018126 |
| Ramucirumab | Placebo | Second line | Approved (US FDA, NMPA; ongoing) | Zhu et al., 2015130; Kudo et al., 2020132 |